Filing Flows

Filing Flows › Vera Therapeutics (VERA) › Next earnings date

Vera Therapeutics (VERA) earnings: beat the estimate

Vera Therapeutics (VERA) reported on Nov 5, 2026 and beat the EPS estimate: −$1.30 against −$1.62 (+19.7%). Revenue was $10.3M for Q3 2026. It beat the EPS estimate in 40% of the quarters on record.

Last result+19.7% vs estimate
Beat rate40%

The last report

Vera Therapeutics reported revenue of $10.3M for the third quarter 2026, net loss $93.7M. How it makes money → · Every quarter →

Vera Therapeutics: EPS against the estimate, last 5 reportsVera Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$1.13−$1.26Nov 25−$1.27−$1.39Feb 26−$1.37−$1.69May 26−$1.59−$1.52Aug 26−$1.62−$1.30Nov 26
Latest (Nov 26): Estimate −$1.62, Reported −$1.30.

Vera Therapeutics' latest quarter

Vera Therapeutics, Q3 2026: revenue $10.3M, operating margin -931.2%, net loss $93.7M, operating cash flow −$99.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did Vera Therapeutics beat earnings?

Vera Therapeutics (VERA) reported on Nov 5, 2026 and beat the EPS estimate: −$1.30 against −$1.62 (+19.7%).

When does VERA report earnings?

The next date is not set yet.

Does Vera Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.